Neurofibromin Homologs Ira1 and Ira2 Affect Glycerophosphoinositol Production and Transport in *Saccharomyces cerevisiae*

Andrew C. Bishop,† Beth A. Surlow,† Puneet Anand,‡ Katherine Hofer,§ Matthew Henkel, and Jana Patton-Vogt*

Department of Biological Sciences, Duquesne University, Pittsburgh, Pennsylvania 15282

Received 27 July 2009/Accepted 24 August 2009

Saccharomyces cerevisiae **produces extracellular glycerophosphoinositol through phospholipase-mediated turnover of phosphatidylinositol and transports glycerophosphoinositol into the cell upon nutrient limitation. A screening identified the RAS GTPase-activating proteins Ira1 and Ira2 as required for utilization of glycerophosphoinositol as the sole phosphate source, but the RAS/cyclic AMP pathway does not appear to be involved in the growth phenotype. Ira1 and Ira2 affect both the production and transport of glycerophosphoinositol.**

Membrane phospholipids are continually synthesized and degraded as cells grow and respond to environmental conditions. A major pathway of phosphatidylinositol (PI) turnover in *Saccharomyces cerevisiae* is its deacylation to produce extracellular glycerophosphoinositol (GroPIns) (3). Plb3, an enzyme with phospholipase B (PLB)/lysophospholipase activity, is thought to be primarily responsible for the production of extracellular GroPIns, with Plb1 playing a lesser role (11, 12, 13). GroPIns is transported into the cell by the Git1 permease (17). *GIT1* expression is upregulated by phosphate limitation and inositol limitation. In fact, GroPIns can act as the cell's sole source of both inositol (17) and phosphate (1).

A screening for gene products involved in the process by which GroPIns enters the cellular metabolism identified Ira1 and Ira2, yeast homologs of the mammalian protein neurofibromin. Alterations in *NF1*, the gene encoding neurofibromin, are associated with the pathogenesis of neurofibromatosis type 1, an autosomal dominant genetic disease (4, 5, 25). Ira1 and Ira2 and neurofibromin function as RAS GTPase-activating proteins (RAS GAPs). *S. cerevisiae* Ras1 and Ras2 activate adenylate cyclase to modulate cyclic AMP (cAMP) levels. The binding of cAMP to the regulatory subunits of protein kinase A (Bcy1) results in dissociation and activation of the catalytic subunits (Tpk1 to Tpk3). Ira1 and Ira2 inactivate RAS and thereby downregulate the pathway (18, 19). Hydrolysis of cAMP by the phosphodiesterases encoded by *PDE1* and *PDE2* also downregulate the pathway (7, 20, 23). The RAS/cAMP pathway responds to nutrient signals to modulate fundamental cellular processes, including stress resistance, metabolism, and cell proliferation (7, 20, 21).

Identification of *IRA* **genes as affecting GroPIns metabolism.** To identify genes involved in the metabolic process by which GroPIns is used as a phosphate source, we screened the

*MAT*α viable yeast knockout collection (Research Genetics) for strains displaying compromised growth when GroPIns rather than low P_i was supplied as the phosphate source. Synthetic complete medium, high- P_i (10 mM KH₂PO₄) medium, low-P_i (0.2 mM KH₂PO₄) medium, and GroPIns+ (70 μ M) medium were made as described previously (2). Mutants were transferred by hand pinner from a master plate to a 96-well plate containing low-P_i medium and allowed to grow at 30° C for 3 days. From low-P_i medium, cell inocula were transferred to plates containing GroPIns+ medium. Growth was monitored at 595 nm after 4 days of incubation at 30°C. The ratio of absorbance in low- P_i medium to absorbance in GroPIns+ medium was determined. This screening was performed twice. Mutants with a value of 3 or greater for the ratio of absorbance in low- P_i medium to absorbance in GroPIns+ medium were subjected to a second screening by the monitoring of their growth in test tubes. As expected, the *GIT1* gene was required for growth, and no other mutant displayed a complete growth abatement phenotype (Fig. 1). In particular, we did not identify a gene likely to encode a glycerophosphodiesterase responsible for GroPIns catabolism. A likely explanation for this result is that multiple gene products are involved in the mechanism(s) by which GroPIns enters cellular metabolism. However, a number of strains exhibited a slow-growth phenotype, one of which was the $ira2\Delta$ mutant (Fig. 1A). To confirm the validity of this result, we analyzed growth on GroPIns in strains of the unrelated Σ 1278b background (gifts from M. Cardenas, Duke University), and found that not only the $ira2\Delta$ mutant but also the *ira1* Δ mutant and the *ira1* Δ *ira2* Δ double mutant (Table 1) exhibited greatly reduced growth on GroPIns (Fig. 1B). The $iral\Delta$ mutant was not present in the deletion set screened initially.

To probe the role of the RAS/cAMP in GroPIns metabolism, we analyzed other strains bearing alterations in the pathway. Interestingly, a $pde2\Delta$ mutant that, like the $ira2\Delta$ mutant, exhibits increased cAMP levels (15) was not defective for growth on GroPIns. Similarly, a strain bearing a plasmid-borne hyperactive allele of *RAS2*, *RAS2-V19* (a gift from P. Herman, Ohio State University) (9, 10, 22), was not defective for growth on GroPIns (Fig. 1A). Thus, upregulation of the RAS/cAMP pathway may not be the primary reason for the growth defect

^{*} Corresponding author. Mailing address: Department of Biological Sciences, Duquesne University, Pittsburgh, PA 15282. Phone: (412) 396-1053. Fax: (412) 396-5907. E-mail: pattonvogt@duq.edu.

[†] A. C. Bishop and B. A. Surlow contributed equally to this work.

[‡] Present address: Department of Biochemistry, Duke University Medical Center, Durham, NC 27710.

[§] Present address: Department of Biological Sciences, University of

Published ahead of print on 28 August 2009.

using GroPIns as a phosphate source. Strains in the BY4742 (A) or Σ 1278b (B) background were grown overnight in low-P_i medium. Cells were transferred to low-P_i or GroPIns+ medium (A_{600} = 0.005). Absorbance was recorded after 48 h of growth at 30°C. Wild-type cells transformed with empty vector pRS415 (vector) or plasmid pPHY453, containing the hyperactive *RAS2* allele *RAS2-* $V19$ ($RAS2^{V19}$), were also assayed (A). Readings are means \pm standard errors of the means of results of at least two independent experiments.

seen in the absence of Ira1 or Ira2. Not surprisingly, $ras1\Delta$ and $ras2\Delta$ mutants, expected to downregulate the RAS/cAMP pathway, were not defective for growth on GroPIns (data not shown).

A trivial explanation for the inability of strains bearing mutations in the *IRA* genes to utilize GroPIns as a phosphate source is that the cells are less robust than wild-type cells and die before they are able to induce the metabolism required to utilize GroPIns. To test this, we compared the survival of the wild type and an $ira1\Delta$ *ira* 2Δ mutant upon phosphate starvation and found no difference between the two strains (data not shown).

An *ira1 ira2* **mutant exhibits altered GroPIns transport activity.** To determine the cause of the defect in GroPIns utilization that occurs upon deletion of *IRA1* or *IRA2*, we measured GroPIns transport activity (1) under low-P_i conditions. In cells harboring single-deletion mutations, GroPIns transport was similar to that of the wild-type strain or only slightly reduced (Fig. 2A). However, the simultaneous deletion of *IRA1* and *IRA2* resulted in a clear reduction in activity. These results do not explain the growth defects seen in the single-deletion mutants, but they do indicate a role for Ira1 or Ira2 in regulating Git1. A complete understanding of the nature of the regulation of GroPIns transport by Ira1 or Ira2 will be the focus of future studies.

Deletion of *IRA1* **or** *IRA2* **increases the extracellular accumulation of GroPIns.** We next monitored the effect of Ira1 or Ira2 upon extracellular production of GroPIns via PI deacylation. Cells were grown overnight in medium containing 3 Ci/ml of [2-3 H]inositol. Cells were harvested, washed, and reinoculated to an A_{600} of 0.2 in high-P_i medium, the condition under which extracellular GroPIns accumulates (17). At various times, aliquots of the cultures were centrifuged, and the inositol compounds in the supernatant were separated (16). The *ira1* Δ , *ira2* Δ , and *ira1* Δ *ira2* Δ mutants accumulated roughly twice as much extracellular GroPIns as the wild-type strain (Fig. 2B) upon entrance to stationary phase. The lack of an additive effect upon GroPIns formation in the double mutant compared to formation in the single mutants may be explained by substrate availability. In other words, there may be a limited amount of plasma membrane-associated PI available for PLB-mediated turnover. Whereas an *ira1 ira2* dou-

^a WT, wild type.

FIG. 2. Ira1 and Ira2 affect GroPIns transport activity and GroPIns production. (A) Cells grown to log phase in low- P_i medium were assayed for GroPIns transport activity. Data represent means \pm standard errors of the means of results of two independent experiments performed in duplicate. (B) Cells prelabeled with [³H]inositol were reinoculated into fresh high- P_i medium, and the amount of extracellular GroPIns was determined following 22 h of growth. Data are means \pm standard errors of the means of results of at least three independent experiments and are reported as the percentage of total [³H]inositol label found as extracellular GroPIns normalized for culture density.

ble mutant exhibits an increase in *PLB1* and *PLB3* transcript levels as measured by real-time reverse transcriptase PCR (data not shown), no such increase was detectable in the $ira1\Delta$ or *ira2* mutant. Thus, Ira1 or Ira2 regulation of the PLB activity leading to GroPIns formation likely occurs at multiple levels and will be the focus of future studies. Another explanation is that yet another, uncharacterized, phospholipase exists for the formation of GroPIns in the absence of Ira1 or Ira2. Importantly, GroPIns transport does not occur under the growth conditions of the experiment (high P_i), so diminished transport cannot explain the increased accumulation of GroPIns in the absence of Ira1 or Ira2.

In summary, this study indicates a role for Ira1 and Ira2 in regulation of both the production of extracellular GroPIns and its transport into the cell. In addition, we show that Ira1 and Ira2 are required for the utilization of GroPIns as a phosphate source under conditions in which transport of GroPIns into the cell is normal. However, we were unable to show a linkage between hyperactivation of the RAS/cAMP pathway, which occurs upon deletion of *IRA1* or *IRA2*, and the growth phenotype. Future studies will focus on determining the mechanism(s) for the growth disturbance, including whether it involves the RAS/cAMP pathway or other, less defined functions of Ira and Ira2. Growth is a multifactorial process, and a combination of disturbances, some involving heightened signaling through the RAS/cAMP pathway and some not, may contribute to alterations in the cell's ability to utilize GroPIns as a phosphate source. Ira1 and Ira2 are large proteins, each over 3,000 amino acids. The RAS GAP-related domain of each protein is contained within a few hundred amino acids, and C-terminal regions of approximately 200 amino acids bind to Gpb1 or Gpb2 and are important for protein stability (8). In addition, yeast Ira1 and Ira2 proteins and the human neurofibromin type 1 protein all contain bipartite phospholipid binding modules consisting of a Sec14 homologous segment and a pleckstrin homology-like domain (6). Both in vitro phospholipid binding and lipid exchange activity have been documented for neurofibromin (24), suggesting that Ira1 and Ira2 may have similar activities. Indeed, Ira1 appears to play a membrane-anchoring role for adenylate cyclase in addition to its role as a RAS GAP (14). It is tempting to speculate that Ira1 or Ira2 might also play a role in the membrane association or activation of an enzyme or enzymes responsible for the metabolism of internalized GroPIns. A test of that hypothesis awaits the identification of the gene products involved in the process by which GroPIns enters cellular metabolism.

This work was supported by National Institutes of Health grant GM59817 to J.P.-V.

We thank M. Cardenas for the gift of strains and P. Herman for the gift of plasmids. We thank Lindsay Chromiak and David Ekpin for technical assistance.

REFERENCES

- 1. **Almaguer, C., W. Cheng, C. Nolder, and J. Patton-Vogt.** 2004. Glycerophosphoinositol, a novel phosphate source whose transport is regulated by multiple factors in Saccharomyces cerevisiae. J. Biol. Chem. **279:**31937–31942.
- 2. **Almaguer, C., E. Fisher, and J. Patton-Vogt.** 2006. Posttranscriptional regulation of Git1p, the glycerophosphoinositol/glycerophosphocholine transporter of Saccharomyces cerevisiae. Curr. Genet. **50:**367–375.
- 3. **Angus, W. W., and R. L. Lester.** 1975. The regulated catabolism of endogenous and exogenous phosphatidylinositol by Saccharomyces cerevisiae leading to extracellular glycerophosphorylinositol and inositol. J. Biol. Chem. **250:**22–30.
- 4. **Ballester, R., D. Marchuk, M. Boguski, A. Saulino, R. Letcher, M. Wigler, and F. Collins.** 1990. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell **63:**851–859.
- 5. **Buchberg, A. M., L. S. Cleveland, N. A. Jenkins, and N. G. Copeland.** 1990. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature **347:**291– 294.
- 6. **D'Angelo, I., S. Welti, F. Bonneau, and K. Scheffzek.** 2006. A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein. EMBO Rep. **7:**174–179.
- 7. **Dechant, R., and M. Peter.** 2008. Nutrient signals driving cell growth. Curr. Opin. Cell Biol. **20:**678–687.
- 8. **Harashima, T., S. Anderson, J. R. Yates III, and J. Heitman.** 2006. The kelch proteins Gpb1 and Gpb2 inhibit Ras activity via association with the yeast RasGAP neurofibromin homologs Ira1 and Ira2. Mol. Cell **22:**819–830.
- 9. **Howard, S. C., A. Hester, and P. K. Herman.** 2003. The Ras/PKA signaling pathway may control RNA polymerase II elongation via the Spt4p/Spt5p complex in Saccharomyces cerevisiae. Genetics **165:**1059–1070.
- 10. **Kataoka, T., S. Powers, S. Cameron, O. Fasano, M. Goldfarb, J. Broach, and M. Wigler.** 1985. Functional homology of mammalian and yeast RAS genes. Cell **40:**19–26.
- 11. **Lee, K. S., J. L. Patton, M. Fido, L. K. Hines, S. D. Kohlwein, F. Paltauf, S. A. Henry, and D. E. Levin.** 1994. The Saccharomyces cerevisiae PLB1 gene encodes a protein required for lysophospholipase and phospholipase B activity. J. Biol. Chem. **269:**19725–19730.
- 12. **Merkel, O., M. Fido, J. A. Mayr, H. Pruger, F. Raab, G. Zandonella, S. D. Kohlwein, and F. Paltauf.** 1999. Characterization and function in vivo of two novel phospholipases B/lysophospholipases from Saccharomyces cerevisiae. J. Biol. Chem. **274:**28121–28127.
- 13. **Merkel, O., O. V. Oskolkova, F. Raab, R. El-Toukhy, and F. Paltauf.** 2005. Regulation of activity in vitro and in vivo of three phospholipases B from Saccharomyces cerevisiae. Biochem. J. **387:**489–496.
- 14. **Mitts, M. R., J. Bradshaw-Rouse, and W. Heideman.** 1991. Interactions

between adenylate cyclase and the yeast GTPase-activating protein IRA1. Mol. Cell. Biol. **11:**4591–4598.

- 15. **Park, J. I., C. M. Grant, and I. W. Dawes.** 2005. The high-affinity cAMP phosphodiesterase of Saccharomyces cerevisiae is the major determinant of cAMP levels in stationary phase: involvement of different branches of the Ras-cyclic AMP pathway in stress responses. Biochem. Biophys. Res. Commun. **327:**311–319.
- 16. **Patton, J. L., L. Pessoa-Brandao, and S. A. Henry.** 1995. Production and reutilization of an extracellular phosphatidylinositol catabolite, glycerophos-phoinositol, by *Saccharomyces cerevisiae*. J. Bacteriol. **177:**3379–3385.
- 17. **Patton-Vogt, J. L., and S. A. Henry.** 1998. GIT1, a gene encoding a novel transporter for glycerophosphoinositol in Saccharomyces cerevisiae. Genetics **149:**1707–1715.
- 18. **Tanaka, K., B. K. Lin, D. R. Wood, and F. Tamanoi.** 1991. IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase-activating protein. Proc. Natl. Acad. Sci. USA **88:**468–472.
- 19. **Tanaka, K., K. Matsumoto, and A. Toh-e.** 1989. *IRA1*, an inhibitory regulator of the *RAS*-cyclic AMP pathway in *Saccharomyces cerevisiae*. Mol. Cell. Biol. **9:**757–768.
- 20. **Thevelein, J. M., and J. H. de Winde.** 1999. Novel sensing mechanisms and targets for the cAMP-protein kinase A pathway in the yeast Saccharomyces cerevisiae. Mol. Microbiol. **33:**904–918.
- 21. **Thevelein, J. M., R. Gelade, I. Holsbeeks, O. Lagatie, Y. Popova, F. Rolland, F. Stolz, S. Van de Velde, P. Van Dijck, P. Vandormael, A. Van Nuland, K. Van Roey, G. Van Zeebroeck, and B. Yan.** 2005. Nutrient sensing systems for rapid activation of the protein kinase A pathway in yeast. Biochem. Soc. Trans. **33:**253–256.
- 22. **Toda, T., I. Uno, T. Ishikawa, S. Powers, T. Kataoka, D. Broek, S. Cameron, J. Broach, K. Matsumoto, and M. Wigler.** 1985. In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell **40:**27–36.
- 23. **Weeks, G., and G. B. Spiegelman.** 2003. Roles played by Ras subfamily proteins in the cell and developmental biology of microorganisms. Cell. Signal. **15:**901–909.
- 24. **Welti, S., S. Fraterman, I. D'Angelo, M. Wilm, and K. Scheffzek.** 2007. The sec14 homology module of neurofibromin binds cellular glycerophospholipids: mass spectrometry and structure of a lipid complex. J. Mol. Biol. **366:** 551–562.
- 25. **Xu, G. F., B. Lin, K. Tanaka, D. Dunn, D. Wood, R. Gesteland, R. White, R. Weiss, and F. Tamanoi.** 1990. The catalytic domain of the neurofibromatosis type 1 gene product stimulates *ras* GTPase and complements *ira* mutants of S. cerevisiae. Cell **63:**835–841.
- 26. **Zurita-Martinez, S. A., and M. E. Cardenas.** 2005. Tor and cyclic AMPprotein Kinase A: two parallel pathways regulating expression of genes required for cell growth. Eukaryot. Cell **4:**63–71.